Menopausal Hormone Therapy: Benefits, Risks and What the Women’s Health Initiative Really Showed

In the summer of 2002, headlines announced that hormone therapy caused breast cancer, heart attacks and strokes. Millions of women stopped their prescriptions, and many doctors stopped offering them. Some of the women I see today went through menopause in the years that followed and simply suffered through hot flashes and sleepless nights because they were told hormones were dangerous.

The science has moved on considerably since then. In this article, I’ll explain what the Women’s Health Initiative actually studied, how experts read it today, and how I help women weigh benefits against risks.

What the WHI studied

The Women’s Health Initiative hormone trials were large, well-designed randomized studies. They tested two regimens against placebo:

• Estrogen plus progestin (conjugated equine estrogens with medroxyprogesterone acetate) in women with a uterus.
• Estrogen alone in women who had had a hysterectomy.

The estrogen-plus-progestin arm was stopped early in 2002 because of a small increase in breast cancer, along with increases in stroke, blood clots and heart events. There were also fewer fractures and colorectal cancers.

Why experts reinterpreted the findings

The average participant was in her early sixties, and many were more than a decade past menopause. That’s important, because most women start hormone therapy around 50 for symptoms. Later analyses, including long-term follow-up published in 2013, pointed to several key insights:

• Age and timing matter. Women who start therapy before 60 or within about ten years of menopause generally have a more favorable balance of benefits and risks. This is often called the timing hypothesis.
• Absolute risks are small for healthy younger women, even where relative risks rise.
• Estrogen alone behaved differently. In women without a uterus, estrogen alone did not increase breast cancer risk in the WHI.
• Route may matter. Observational data suggest transdermal estrogen (patch, gel, spray) carries a lower clot risk than oral estrogen.

The North American Menopause Society’s 2022 position statement concluded that for women under 60 or within ten years of menopause without contraindications, the benefits of hormone therapy generally outweigh the risks for treating bothersome symptoms. In late 2025, the FDA also announced it would move to remove the broad boxed warnings from many menopausal hormone therapy products, reflecting this updated understanding. Labeling still lists important risks, and individual evaluation remains essential.

Benefits of hormone therapy

• Hot flashes and night sweats. Estrogen is the most effective treatment available.
• Sleep and quality of life, often through symptom relief.
• Genitourinary symptoms such as vaginal dryness and painful intercourse. Low-dose vaginal estrogen treats these with minimal absorption.
• Bone protection, reducing fracture risk.

Risks and who should not use it

Hormone therapy is generally not appropriate for women with:

• A history of breast or endometrial cancer, or other estrogen-sensitive cancers.
• A history of blood clots, stroke or heart attack.
• Active liver disease.
• Unexplained vaginal bleeding, which needs evaluation first.

Women with a uterus who take estrogen need a progestogen to protect the uterine lining. Therapy should be reviewed at least yearly, with regular mammograms and attention to blood pressure.

A note on “bioidentical” hormones

Several FDA-approved products contain estradiol and progesterone that are chemically identical to the body’s own hormones. Custom-compounded hormone preparations are a separate category: they are not FDA-approved, and professional societies advise caution about their consistency and the lack of large safety trials. I encourage women to ask exactly what they’re being prescribed and why.

How I approach it

1. A detailed conversation about symptoms and goals.
2. A review of personal and family history for cancer, clots and heart disease.
3. Relevant lab work and screening.
4. The lowest effective dose and a route suited to your risk profile.
5. Regular follow-up.

For genitourinary symptoms, nonhormonal options including women’s sexual wellness treatments may also fit.

Frequently asked questions

Is hormone therapy safe?

For healthy women under 60 or within ten years of menopause, current expert guidance finds the benefits generally outweigh the risks for bothersome symptoms. Individual evaluation is essential.

Does hormone therapy cause breast cancer?

Combined estrogen and progestin was linked to a small increase in breast cancer risk in the WHI. Estrogen alone did not increase it in women without a uterus.

How long can I stay on hormone therapy?

There is no universal cutoff. Duration should be reviewed with your doctor at least yearly.

Is vaginal estrogen risky?

Low-dose vaginal estrogen has minimal absorption and is considered low risk for most women.

Let’s talk about your symptoms

Our hormone optimization program offers a careful, individualized review of menopausal options. Schedule a complimentary, no-commitment consultation.

• Hudson, OH: 50 W Streetsboro St, Suite 2 · (330) 460-5915
• Barboursville, WV: 1 Chateau Grove Ln · (304) 520-0461

Ask about Easy Pay financing.

References: Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002. · Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013. · The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022.

This article is for general information only and is not medical advice. Treatments are provided only after consultation and evaluation by a licensed provider. Individual results vary.